APP’s lyophilized Oxaliplatin for Injection receives FDA marketing approval APP Pharmaceuticals, Inc., a owned subsidiary of Fresenius Kabi Pharmaceuticals Holding wholly, Inc., announced today it received acceptance from the U.S. Food and Medication Administration to market Oxaliplatin for Injection , 50 mg and 100 mg. APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. Regarding to IMS data, U.S. Relating to 2009 IMS data, combined U.S.35 billion.Vaccines have proven to be largely ineffective in stopping the pass on of the virus, and currently there are no plans for their make use of in the fight against the epidemic. A lesson for consumers The known fact our food supply can be affected by outbreaks of disease, not forgetting the implications of consuming GMO-tainted foods as well as other unhealthy chemicals that find their way to the dining room table due to mass production methods, means that the more we are able to grow and create our own healthy, organic meals, the better away we are. And when food shortages turn into a real issue, home meals production will become an essential key to survival.